Thyroid Function Among Pediatric Patients With DM

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05717933
Collaborator
(none)
70
13.9

Study Details

Study Description

Brief Summary

Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: thyroid hormones

Detailed Description

Type-I diabetes mellitus is an auto immune disease. It is the most common type of diabetes in children and adolescents. It is also the most common chronic disease in children in the developed countries. The illness is characterized by the body's inability to produce insulin due to the autoimmune destruction of the beta cells in the pancreas. Globally, it is estimated that there are almost 500,000 children aged under 15 years with type 1diabetes, with large geographical variations in incidence.

  • Furthermore Between 10 to 70% of these children present in Diabetic Ketoacidosis (DKA) as their first presentation of the disease.

  • In addition It can be associated with other auto immune disorders that may influence the control of diabetes by disruption of the function of respective organs and enhance the opportunity of developing DKA as the first manifestation of their disease.

  • In particular, autoimmune thyroiditis (AIT) is the most common disorder associated with type 1 Diabetes Mellitus.

  • AIT and type 1 Diabetes Mellitus have a common genetic background and similar pathogenesis; hence, they could occur in the same individual or family. The prevalence of thyroid autoantibodies in children with type1 Diabetes Mellitus ranges from 3% to 50% in different countries and populations, which is markedly higher than in the general population (range, 1% to 4%).

  • Besides thyroid autoantibodies can be detected at the initial diagnosis and after it.

  • Thyroiditis is often clinically silent but it may progress to autoimmune thyroid disease (AITD), recognized as overt or subclinical hypothyroidism or hyperthyroidism.

  • The American Diabetes Association (ADA) recommended screening Thyroid-Stimulating hormone after diagnosis of diabetes and then after every one to two years. It also recommended that patients found to have positive anti-Thyroid Peroxidase antibodies with normal thyroid function tests should be screened more frequently, every six months to a year .

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Thyroid Function Among Pediatric Patients With Type 1 Diabetes Mellitus at Firs Presentation, From Patients' Characteristics to Disease Severity
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Mar 30, 2024
Anticipated Study Completion Date :
Mar 30, 2024

Outcome Measures

Primary Outcome Measures

  1. thyroid abnormalities among children and adolescents with type 1 diabetes mellitus when its first detected and its relationship with disease-related variables. [Baseline]

    The aim of this study was to detect the prevalence of thyroid functions TSH,T3,T4 abnormalities and the relationship of positive anti-thyroid antibodies to potential risk factors, including, age, gender, duration of diabetes among children and adolescents with type 1 diabetes mellitus when its first detected

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 18 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
    • patients between 2 year and <18 years of age in both sex
  • patients with T1DM that had not been on any thyroid medication

Exclusion Criteria:
    • patients <2 years and >18 years of age in both sex
  • patient with systemic illnesses, diagnosed thyroid disorders and patients taking medications

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mohamed Fathy Abd ELhay, Principal Investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT05717933
Other Study ID Numbers:
  • thyroid function in DM
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2023